Brief: Sensorion End-June Operating Loss Widens To EUR 12.2 Mln

Sensorion SA

22/09/2022 06:40

Sept 22 (Reuters) - SENSORION SA  ALSEN.PA :
    * SENSORION REPORTS 2022 FIRST HALF RESULTS
    * ENDED Q2 2022 WITH A CASH POSITION OF EUR 39M
    * GJB2-GT ADVANCING AFTER PROMISING RESULTS, CANDIDATE
SELECTION
EXPECTED IN 2H 2022
    * CONTINUED PROGRESS TOWARD PLANNED DEVELOPMENT FOR SENS-401
AND
GENE THERAPY PROGRAMS
    * POSITIVE PROGRESS FOR TWO CLINICAL TRIALS FOR SENS-401: IN
CISPLATIN-INDUCED OTOTOXICITY (CIO) AND TO PREVENT RESIDUAL
HEARING LOSS FOLLOWING COCHLEAR IMPLANTATION
    * DEVELOPMENT MILESTONE ACHIEVED FOR OTOF-GT PROGRAM WITH
DELIVERY
OF BATCHES FOR TOXICOLOGY STUDY; PLAN TO FILE CLINICAL TRIAL
APPLICATION IN 1H 2023
    * COMPANY EXPECTS CASH POSITION OF EUR 39M ON JUNE 30, 2022,
TO BE
SUFFICIENT TO FUND ITS OPERATIONS UNTIL END OF Q3 2023
    * END-JUNE OPERATING INCOME EUR 1.9 MLN VS EUR 1.6 MLN YR
AGO
    * END-JUNE NET LOSS EUR 12.3 MLN VS LOSS EUR 6.2 MLN YR AGO
    * END-JUNE OPERATING LOSS EUR 12.2 MLN VS LOSS EUR 6.1 MLN
YR AGO

        
 Source text for Eikon:  ID:nBw3rSspMa 
 Further company coverage:  ALSEN.PA  
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))